← SynDRA
ZALEPLON
SynDRA canonical compound SYN0008486 — structure-anchored drug synonym record
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | GABRA1 |
|---|
| Mechanism of action | Benzodiazepine receptor agonist |
|---|
All known targets
- GABRA1
- GABRG2
- GABRA2
- GABRB1
- GABRB2
- GABRB3
Mechanisms of action (all sources)
- Benzodiazepine receptor agonist
- GABRA1 POSITIVE ALLOSTERIC MODULATOR
- GABA A receptor alpha-1/beta-1/gamma-2 positive allosteric modulator
- GABRG2 POSITIVE ALLOSTERIC MODULATOR
- GABRB1 POSITIVE ALLOSTERIC MODULATOR
- GABRA1 MODULATOR
- GABRB3 POSITIVE ALLOSTERIC MODULATOR
- GABRA2 POSITIVE ALLOSTERIC MODULATOR
- GABRB2 POSITIVE ALLOSTERIC MODULATOR
Drug classes
- GABA A Agonists
- Anticonvulsants
- Central Nervous System Agents
- Central Nervous System Depressants
- GABA Agents
- GABA Modulators
- Hypnotics and Sedatives
- Neurotransmitter Agents
- gamma-Aminobutyric Acid A Receptor Agonist
ATC classes
- N05C · HYPNOTICS AND SEDATIVES
Cross-references
Synonyms
- sonata
- ZAL-846
- CL 284,846
- CL-284846
- Zaleplone
- Zerene
- L-846
- L846
- LJC-10846
- LJC10846
- SKP-1041
- Sonata
- Zaleplon civ
- Zalaplon
- AZ-007
- CL284,846
- Sonata (TN)
- Staccato-zaleplon
- Starnoc (TN)
- Zaleplon [USAN:INN]
- Zaleplon (JAN/USAN/INN)
- N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-ethylacetamide
- N-(3-(3-Cyanopyrazolo(1,5-a)pyrimidin-7-yl)phenyl)-N-ethylacetamide
- 3'-(3-Cyanopyrazolo(1,5-a)pyrimidin-7-yl)-N-ethylacetanilide
- 3'-(3-Cyanopyrazolo(1,5-alpha)pyrimidin-7-yl)-N-ethylacetanilide
- CL 284846
- ZAL 846
- DEA No. 2781
- S62U433RMH
- CHEBI:10102
- N-(3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl)-N-ethylacetamide
- NCGC00160525-01
- N-(3-{3-cyanopyrazolo[1,5-a]pyrimidin-7-yl}phenyl)-N-ethylacetamide
- SMR000238180
- CAS-151319-34-5
- UNII-S62U433RMH
- Zaleplon AP
- Zaleplon [USAN:USP:INN:BAN]
Reported adverse events
- Amnesia
- Asthenia
- Colitis
- Dizziness
- Epistaxis
- Hallucination
- Headache
- Hyperacusis
- Hypertonia
- Malaise
- Nausea
- Parosmia
Look up ZALEPLON in the interactive SynDRA portal →